[Value of multiplex nucleic acid amplification tests (NAATs) in the medical management of upper respiratory tract infections]
Belhabib R, Carbonneil C
Record ID 32018016121
French
Original Title:
Intérêt des techniques d’amplification des acides nucléiques (TAAN) multiplex dans la prise en charge médicale des infections des voies respiratoires supérieures
Authors' objectives:
The objective of this assessment was to determine whether multiplex nucleic acid amplification tests (NAATs) have documented clinical utility in routine care for upper respiratory tract infections: acute rhinopharyngitis, acute tonsillitis, acute rhinosinusitis, acute otitis media, acute laryngeal infections and influenza-like illness. Where clinical utility was established, the aim was to define the clinical indications, the infectious agents to be screened for, the expected diagnostic performance and the role of this procedure in the care pathway.
Authors' results and conclusions:
Upper respiratory tract infections are mostly viral, benign and self-limiting, and no clinical benefit of NAATs has been demonstrated in outpatient care. NAATs are therefore not recommended for acute rhinopharyngitis, acute tonsillitis, acute rhinosinusitis, acute otitis media, acute laryngeal infections, or influenza-like illness managed in the outpatient setting. However, a quadriplex NAAT (influenza A and B viruses, respiratory syncytial virus and SARS-CoV-2) is indicated for influenza-like illness in emergency departments, hospitalised patients and residential care facilities, in symptomatic patients during epidemic periods, when a rapid result is likely to change patient management immediately (antiviral treatment, discontinuation of antibiotics, isolation measures). A nasopharyngeal swab is the first-line sample. Each target should reach a minimum sensitivity of 90% and a minimum specificity of 95%.
Authors' recommendations:
The HAS issued a favourable opinion on the reimbursement of the quadriplex NAAT for influenza-like illness in the hospital setting and in residential care facilities, and an unfavourable opinion in all other situations assessed. The HAS points out that: ‒ like all diagnostic tests, NAATs should be performed following a physical examination of the patient; ‒ their diagnostic performance depends on the quality of the sample and on the detection window of the nucleic acids of the agents concerned; ‒ a NAAT is only recommended when it could change the patient’s clinical management; ‒ NAATs cannot always distinguish active infection from carriage, which requires close dialogue between clinicians and biologists; ‒ their results must be delivered within a time frame compatible with optimal patient care.
Authors' methods:
The HAS’ standard method for the assessment of professional procedures was used. This method included: i) a systematic search of synthesised literature (systematic reviews, HTA reports and clinical practice guidelines published between 2015 and 2025) with selection based on PICOS criteria and critical appraisal using AMSTAR 2 and AGREE II; ii) the consultation of twelve individual experts; and iii) the collection of the perspective of stakeholders (professional bodies, patient associations and industry) concerned by the subject.
Authors' identified further research:
Impact of syndromic NAATs in outpatient care ‒ Clinical utility: available data mainly come from hospital settings. Studies are needed to assess the diagnostic performance, the clinical and organisational impact, and the role of syndromic NAATs in the outpatient care pathway. ‒ Rapid diagnostic tests: a prospective comparative real-world study is ongoing to assess their diagnostic performance and their impact on inappropriate antibiotic prescribing and repeat consultations. The HAS will update its conclusions in light of these results. Harmonisation of terminology ‒ The heterogeneous terms used for upper respiratory tract infections (common cold, rhinitis, rhinopharyngitis, sinusitis) are a source of diagnostic confusion and inappropriate prescriptions. The HAS encourages professional bodies to adopt a common terminology, in line with the proposals of the French Society of Otorhinolaryngology and the EPOS 2020 and ICAR-RS 2021 guidelines.
Details
Project Status:
Completed
Year Published:
2026
URL for published report:
https://www.has-sante.fr/upload/docs/application/pdf/2026-01/dir3/rapport_taan_infections_respiratoires_hautes.pdf
Requestor:
French Directorate General of Health Care Provision (DGOS), as part of a multi-year request asking HAS to assess nucleic acid amplification tests (NAATs) in various infectious diseases, in order to inform public decision-making regarding their reimbursement.
English language abstract:
There is no English language summary available
Publication Type:
Rapid Review
Country:
France
MeSH Terms
- Respiratory Tract Infections
- Nucleic Acid Amplification Techniques
- Tonsillitis
- Rhinosinusitis
- Pharyngitis
- Laryngeal Diseases
- Influenza, Human
- Otitis Media
Keywords
- NAAT
- nucleic acid amplification tests
- upper respiratory tract infections
- influenza-like illness
- influenza
- respiratory syncytial virus
- SARS-CoV-2
- quadriplex PCR
- syndromic testing
- rhinopharyngitis
- tonsillitis
- rhinosinusitis
- acute otitis media
- diagnostic stewardship
- antimicrobial stewardship
- health technology assessment
Contact
Organisation Name:
Haute Autorité de Santé
Contact Address:
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name:
has.seap.secretariat@has-sante.fr
Contact Email:
has.seap.secretariat@has-sante.fr
Copyright:
<p>Haute Autorite de Sante/French National Authority for Health (HAS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.